Dr Shannon MacDonald speaks to ecancer about RadComp trial. The RadComp phase III randomised trial compared proton radiotherapy (PrRT) versus photon radiotherapy (PhRT) for patients with non-metastatic breast cancer, focusing on patient-reported health-related quality of life (HRQoL).

Trial results showed no clinically meaningful differences between proton and photon therapy in fatigue, cosmetic satisfaction, overall HRQoL, or most adverse effects.

Dr MacDonald says that these findings indicate that both proton and photon radiotherapy provide excellent HRQoL in early follow-up for breast cancer patients. Longer-term outcomes, including loco-regional control and cardiac events, will be reported later.